METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting
HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting. The company demonstrated that its proprietary AiLNP platform enables the...
DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
SHANGHAI, July 22, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung...
Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific
SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, attract investment and improve lives, a new expert-driven report finds. Released today, 'On the Cusp of a Cure' White Paper examines Asia Pacific's readiness for the Precision Era –...
OMRON Healthcare Singapore partners with bolttech and QBE to launch innovative embedded health solution
The comprehensive subscription programme offers OMRON customers in Singapore access to personalised health protection and insights SINGAPORE, July 22, 2025 /PRNewswire/ -- Global insurtech bolttech and OMRON Healthcare Singapore, a global leader in innovative medical equipment for health monitoring and therapy, today announced the launch of their Premium Care subscription plan in...
Health In Tech Announces Second Quarter 2025 Financial Results
Revenues of $9.3 million, up 86% YoY; The first-half year revenues of $17.3 million, 89% of full year 2024. Adjusted EBITDA of $1.6 million, up 134% YoY; The first-half year adjusted EBITDA of $2.8 million, 1.2 times full year 2024. Cash balance of $8.1 million. STUART, Fla. , July 22,...
2025 Inaugural Global Chest Wall Surgery Conference Concludes Successfully: Uniting Expertise, Driving Innovation
GUANGZHOU, China, July 21, 2025 /PRNewswire/ -- The inaugural Global Chest Wall Surgery Conference concluded successfully in Guangzhou on July 19, uniting leading medical experts worldwide to share cutting-edge surgical innovations and clinical insights in chest wall surgery. The conference featured a series of high-level academic lectures focusing on the latest developments, advanced techniques, emerging trends, and key issues in...
ICWS Successfully Concludes 2nd Global Program on Cutting-edge Chest Wall Surgery Techniques
GUANGZHOU, China, July 21, 2025 /PRNewswire/ -- The 2nd "Latest Chest Wall Surgery Technique Global Training Program", hosted by the Institute of Chest Wall Surgery (ICWS) of Guangdong Second Provincial General Hospital, was successfully held from July 16 to 18, 2025. The program brought together 10 thoracic surgeons from the United States, Romania, India, Armenia, Pakistan, Malaysia, Mexico, and...
BON Announces $22 Million Distribution Agreement for Weight Loss Products with Beijing Huahai Keyuan Technology Co., Ltd
XI'AN, China, July 21, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural health and personal care industries, today announced it has entered into a non-exclusive sales distribution agreement with Beijing Huahai Keyuan Technology Co. Ltd. ("Huahai Keyuan"). The term of the agreement is 36 months with a...
Bloomage Achieves FDA GMP Audit with Zero-Deficiency, Reinforcing Global Trust
PARSIPPANY, N.J., July 21, 2025 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, has announced it successfully passed the U.S. Food and Drug Administration (FDA)'s on-site GMP audit with a "No Action Indicated" (NAI) result. This is the best possible result, confirming complete compliance with no objectionable conditions ("zero-deficiency"). The FDA's issuance of...
Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer
PHILADELPHIA, July 21, 2025 /PRNewswire/ -- Minaris Advanced Therapies is pleased to announce the appointment of Dr. Orla Cloak as Chief Executive Officer. Dr. Cloak is a seasoned executive with over 20 years of commercial leadership experience in the Pharma and Life Science industries. She brings with her a proven track record...
